相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy
Lara Sanchez-Barroso et al.
ONCOLOGIST (2019)
OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity
Alix F. Leblanc et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Drug Distribution into Peripheral Nerve
Houfu Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review
Tore B. Stage et al.
CLINICAL PHARMACOKINETICS (2018)
Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes
Christine Wegler et al.
MOLECULAR PHARMACEUTICS (2017)
Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study
K. Agergaard et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese
Yuko Tanabe et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions
Marie Lund et al.
DRUGS (2017)
Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel
Tulay Kus et al.
ONCOTARGETS AND THERAPY (2016)
Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)
Ganesh K. Boora et al.
CANCER MEDICINE (2016)
The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
Rishil J. Kathawala et al.
DRUG RESISTANCE UPDATES (2015)
Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats
Liyue Huang et al.
XENOBIOTICA (2015)
Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel
Annemieke J. M. Nieuweboer et al.
CANCER RESEARCH (2014)
Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel
Jean E. Abraham et al.
CLINICAL CANCER RESEARCH (2014)
Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia
Francesco Ceppi et al.
PHARMACOGENOMICS (2014)
The P-Glycoprotein Transport System and Cardiovascular Drugs
Jeffrey D. Wessler et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy
Amteshwar Singh Jaggi et al.
TOXICOLOGY (2012)
Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy
Dawn L. Hershman et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Contribution of Abcc10 (Mrp7) to In Vivo Paclitaxel Resistance as Assessed in Abcc10-/- Mice
Elizabeth A. Hopper-Borge et al.
CANCER RESEARCH (2011)
Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents
Carolyn A. Goard et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer
Henrik Green et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2009)
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel
Tristan M. Sissung et al.
CLINICAL CANCER RESEARCH (2008)
Mechanisms Underlying Chemotherapy-Induced Neurotoxicity and the Potential for Neuroprotective Strategies
S. B. Park et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
Tristan M. Sissung et al.
EUROPEAN JOURNAL OF CANCER (2006)
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics
Jurjen S. Lagas et al.
CLINICAL CANCER RESEARCH (2006)
Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer
H. Yamaguchi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Peripheral neuropathy induced by microtubule-stabilizing agents
JJ Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport
T Sakaeda et al.
PHARMACEUTICAL RESEARCH (2006)
Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes
S Mielke et al.
EUROPEAN JOURNAL OF CANCER (2006)
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid
MT Huisman et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel
NF Smith et al.
CANCER BIOLOGY & THERAPY (2005)
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1
M Nakajima et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Differential interaction of 3-hydroxy-3-methylglutaryl-COA reductase inhibitors with ABCB1, ABCC2, and OATP1B1
CP Chen et al.
DRUG METABOLISM AND DISPOSITION (2005)
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin
JH Hochman et al.
PHARMACEUTICAL RESEARCH (2004)
Taking simvastatin in the morning compared with in the evening: randomised controlled trial
A Wallace et al.
BRITISH MEDICAL JOURNAL (2003)
Effect of valspodar on the pharmacokinetics of unbound paclitaxel
AJ ten Tije et al.
INVESTIGATIONAL NEW DRUGS (2003)
Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031
JS Woo et al.
PHARMACEUTICAL RESEARCH (2003)
Homozygous disruption of the mdr1a p-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs
T Saito et al.
ACTA OTO-LARYNGOLOGICA (2001)
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein
EJ Wang et al.
PHARMACEUTICAL RESEARCH (2001)
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833
I Chico et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors
A Patnaik et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies
PM Fracasso et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
